DOCSLIB.ORG

Pharmacology

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacology The Journal of PHARMACOLOGY And Experimental Therapeutics A Publication of the American Society for Pharmacology and Experimental Therapeutics July 2007 Vol. 322, No. 1 Contents BEHAVIORAL PHARMACOLOGY Decrease in N-Methyl-D-aspartic Acid Receptor-NR2B Subunit Bichoy H. Gabra, Fay K. Kessler, 186 Levels by Intrathecal Short-Hairpin RNA Blocks Group I Joseph K. Ritter, William L. Dewey, and Metabotropic Glutamate Receptor-Mediated Hyperalgesia Forrest L. Smith Downloaded from Antibodies to Nerve Growth Factor Reverse Established Kenneth D. Wild, Di Bian, Dawn Zhu, 282 Tactile Allodynia in Rodent Models of Neuropathic Pain James Davis, Anthony W. Bannon, without Tolerance Tie J. Zhang, and Jean-Claude Louis Induction by Antipsychotics of “Win-Shift” in the Drug Francis Colpaert, Wouter Koek, 288 Discrimination Paradigm Mark Kleven, and Joel Besnard CARDIOVASCULAR jpet.aspetjournals.org Direct Effects of Nicotine on Contractility of the Uterine DaLiao Xiao, Xiaohui Huang, Shumei Yang, 180 Artery in Pregnancy and Lubo Zhang Chronic Treatment with Carvedilol Improves Ca2؉- K. Brixius, R. Lu, B. Boelck, S. Grafweg, 222 Dependent ATP Consumption in Triton X-Skinned Fiber F. Hoyer, C. Pott, U. Mehlhorn, W. Bloch, Preparations of Human Myocardium and R. H. G. Schwinger Modulation of Sympathetic Activity by Tissue Plasminogen Ulrich Schaefer, Sandra Vorlova, 265 at ASPET Journals on September 23, 2021 Activator Is Independent of Plasminogen and Urokinase Takuji Machida, Jerry P. Melchor, Sidney Strickland, and Roberto Levi An in Vitro Study with an Ussing Chamber Showing That Bita Moazed and Linda M. Hiebert 299 Unfractionated Heparin Crosses Rat Gastric Mucosa ␴ 2-Receptor Ligand-Mediated Inhibition of Inwardly Laurent Monassier, Boris Manoury, 341 ,Rectifying K؉ Channels in the Heart Chloe´Bellocq, Jacques Weissenburger Hugues Greney, Diane Zimmermann, Jean-Daniel Ehrhardt, Patrice Jaillon, Isabelle Baro´, and Pascal Bousquet Biomarker Optimization to Track the Antithrombotic and William A. Schumacher, 369 Hemostatic Effects of Clopidogrel in Rats Jeffrey S. Bostwick, Martin L. Ogletree, Anne B. Stewart, Thomas E. Steinbacher, Ji Hua, Laura A. Price, Pancras C. Wong, and Robert P. Rehfuss CELLULAR AND MOLECULAR Nicotine and Ethanol Activate Protein Kinase A Yuichiro Inoue, Lina Yao, 23 ␤␥ Synergistically via Gi Subunits in Nucleus F. Woodward Hopf, Peidong Fan, Accumbens/Ventral Tegmental Cocultures: The Role of Zhan Jiang, Antonello Bonci, and Dopamine D1/D2 and Adenosine A2A Receptors Ivan Diamond □S Neuroprotection by Small Molecule Activators of the Nerve Bo Lin, Michael C. Pirrung, Liu Deng, 59 Growth Factor Receptor Zhitao Li, Yufa Liu, and Nicholas J. G. Webster The Journal of Pharmacology and Experimental Therapeutics (ISSN Single copy: $85.00. GST Tax Number for Canadian subscribers: 0022-3565) is published monthly by the American Society for Phar- BN:13489 2330 RT. Indexed or abstracted by Biochemistry & Bio- macology and Experimental Therapeutics, 9650 Rockville Pike, physics Citation Index®, Biological Abstracts, BIOSIS Previews Data- Bethesda, MD 20814-3995; email: [email protected]; web site: base, BioSciences Information Services, Current Awareness in Bio- www.aspet.org. Periodicals postage paid at Bethesda, MD, and at ad- logical Sciences, Current Contents®/Life Sciences, EMBASE/ ditional mailing offices. POSTMASTER: Send address changes to The Excerpta Medica, Index Medicus, Medical Documentation Service®, Journal of Pharmacology and Experimental Therapeutics, 9650 Rock- PsycINFO, Reference Update®, Research Alert®, Science Citation ville Pike, Bethesda, MD 20814-3995. Subscription rates: U.S.: $850.00 Index®, SciSearch®, and SIIC Data Bases. Copyright © 2007 by the for institutions and $370.00 for non-ASPET members. Outside the American Society for Pharmacology and Experimental Therapeutics. U.S.: $999.00 for institutions and $519.00 for non-ASPET members. All rights reserved. Printed in the U.S.A. Beryllium Induces Premature Senescence in Human Shannon S. A. Coates, Bruce E. Lehnert, 70 Fibroblasts Sunil Sharma, Susan M. Kindell, and Ronald K. Gary □S Oxyntomodulin Differentially Affects Glucagon-Like Peptide-1 Rasmus Jorgensen, Valentina Kubale, 148 ␤ ␣ Receptor -Arrestin Recruitment and Signaling through G s Milka Vrecl, Thue W. Schwartz, and Christian E. Elling In Vitro Pharmacology of Clinically Used Central Nervous R. A. Bakker, M. W. Nicholas, T. T. Smith, 172 System-Active Drugs as Inverse H1 Receptor Agonists E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner Apomine Enhances the Antitumor Effects of Lovastatin on Anke J. Roelofs, Claire M. Edwards, 228 Myeloma Cells by Down-Regulating 3-Hydroxy-3- R. Graham G. Russell, F. Hal Ebetino, methylglutaryl-Coenzyme A Reductase Michael J. Rogers, and Philippa A. Hulley CHEMOTHERAPY, ANTIBIOTICS, AND GENE THERAPY Tumor Priming Enhances Delivery and Efficacy of Dan Lu, M. Guillaume Wientjes, Ze Lu, and 80 Nanomedicines Jessie L.-S. Au Combination Silencer RNA (siRNA) Targeting Bcl-2 Aleksandra A. Pandyra, Randal Berg, 123 Antagonizes siRNA against Thymidylate Synthase in Human Mark Vincent, and James Koropatnick Tumor Cell Lines ENDOCRINE AND DIABETES Downloaded from Nateglinide and Mitiglinide, but Not Sulfonylureas, Induce Makoto Shigeto, Masashi Katsura, 1 Insulin Secretion through a Mechanism Mediated by Calcium Masafumi Matsuda, Seitaro Ohkuma, and Release from Endoplasmic Reticulum Kohei Kaku Pharmacological Profile of the Thyroid Hormone Receptor Gary J. Grover, Celeste Dunn, 385 Antagonist NH3 in Rats Ngoc-Ha Nguyen, Jamie Boulet, Gao Dong, Jason Domogauer, Peter Barbounis, and jpet.aspetjournals.org Thomas S. Scanlan GASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL Cisplatin-Induced Acute Renal Failure Is Associated with an Sarah Faubel, Eli C. Lewis, 8 Increase in the Cytokines Interleukin (IL)-1␤, IL-18, IL-6, Leonid Reznikov, Danica Ljubanovic, and Neutrophil Infiltration in the Kidney Thomas S. Hoke, Hilary Somerset, Dong-Jin Oh, Lawrence Lu, at ASPET Journals on September 23, 2021 Christina L. Klein, Charles A. Dinarello, and Charles L. Edelstein Conditional Deletion of Cytochrome P450 Oxidoreductase in Robert D. Finn, Aileen W. McLaren, 40 the Liver and Gastrointestinal Tract: A New Model for Dianne Carrie, Colin J. Henderson, and Studying the Functions of the P450 System C. Roland Wolf Role of Transforming Growth Factor ␤ in Rat Bladder Maurits M. Barendrecht, 117 Smooth Muscle Cell Proliferation Arthur C. M. Mulders, Henk van der Poel, Maurice J. B. van den Hoff, Martina Schmidt, and Martin C. Michel Centrally Administered Nociceptin/Orphanin FQ (N/OFQ) Melissa A. Burmeister and 324 Evokes Bradycardia, Hypotension, and Diuresis in Mice via Daniel R. Kapusta Activation of Central N/OFQ Peptide Receptors INFLAMMATION, IMMUNOPHARMACOLOGY, AND ASTHMA Neuroinflammation and Behavioral Abnormalities after M. C. Zerrate, M. Pletnikov, S. L. Connors, 16 Neonatal Terbutaline Treatment in Rats: Implications for D. L. Vargas, F. J. Seidler, Autism A. W. Zimmerman, T. A. Slotkin, and C. A. Pardo Attenuation of Ozone-Induced Airway Inflammation and Alison S. Williams, Razao Issa, 351 Hyper-Responsiveness by c-Jun NH2 Terminal Kinase Sum Yee Leung, Puneeta Nath, Inhibitor SP600125 Gregory D. Ferguson, Brydon L. Bennett, Ian M. Adcock, and Kian Fan Chung METABOLISM, TRANSPORT, AND PHARMACOGENOMICS □S Central Nervous System Drug Disposition: The Relationship Scott G. Summerfield, Kevin Read, 205 between in Situ Brain Permeability and Brain Free Fraction David J. Begley, Tanja Obradovic, Ismael J. Hidalgo, Sara Coggon, Ann V. Lewis, Rod A. Porter, and Phil Jeffrey Accelerated Urinary Excretion of Methylmercury following Michael S. Madejczyk, David A. Aremu, 378 Administration of Its Antidote N-Acetylcysteine Requires Tracey A. Simmons-Willis, Mrp2/Abcc2, the Apical Multidrug Resistance-Associated Thomas W. Clarkson, and Protein Nazzareno Ballatori Rifaximin Is a Gut-Specific Human Pregnane X Receptor Xiaochao Ma, Yatrik M. Shah, 391 Activator Grace L. Guo, Ting Wang, Kristopher W. Krausz, Jeffrey R. Idle, and Frank J. Gonzalez Doxorubicin Degradation in Cardiomyocytes Pierantonio Menna, Emanuela Salvatorelli, 408 and Giorgio Minotti NEUROPHARMACOLOGY Using Hapten Design to Discover Therapeutic Monoclonal Eric C. Peterson, Melinda Gunnell, 30 Antibodies for Treating Methamphetamine Abuse Yingni Che, Robyn L. Goforth, F. Ivy Carroll, Ralph Henry, Huimin Liu, and S. Michael Owens Competitive Antagonism between the Nicotinic Allosteric Cristiane Lopes, Edna F. R. Pereira, 48 Potentiating Ligand Galantamine and Kynurenic Acid at ␣7* Hui-Qiu Wu, Puranik Purushottamachar, Nicotinic Receptors Vincent Njar, Robert Schwarcz, and Edson X. Albuquerque In Vivo Effect of Venlafaxine on Locus Coeruleus Neurons: Esther Berrocoso and Juan Antonio Mico 101 ␣ Role of Opioid, 2-Adrenergic, and 5-Hydroxytryptamine1A Receptors Olanzapine Increases RGS7 Protein Expression via Rakesh K. Singh, Ju Shi, 133 Stimulation of the Janus Tyrosine Kinase-Signal Transducer Bozena W. Zemaitaitis, and Nancy A. Muma Downloaded from and Activator of Transcription Signaling Cascade Region-Specific Overexpression of P-glycoprotein at the E. A. van Vliet, R. van Schaik, 141 Blood-Brain Barrier Affects Brain Uptake of Phenytoin in P. M. Edelbroek, R. A. Voskuyl, S. Redeker, Epileptic Rats E. Aronica, W. J. Wadman, and J. A. Gorter Selectivity of ␦- and ␬-Opioid Ligands Depends on the Route Mary M. Lunzer and Philip S. Portoghese 166 of Central Administration in Mice jpet.aspetjournals.org
Load more

Recommended publications
  • Download Product Catalog
    Total Quality Medications Product Portfolio Rx Product name Dosage form Generic name Pack size Indications A- Alimentary tract and metabolism A02B – Proton pump inhibitor Omecarbex 20 mg H.G Cap Omeprazole +Na 20 Caps Acid reflux and Ulcers Omecarbex 40 mg H.G Cap Carbonate 20 Caps Acid reflux and Ulcers A06A - Laxatives Amiprostone 8 mcg S.G Cap Lubiprostone 20 Capsules Laxative Amiprostone 24 mcg S.G Cap Lubiprostone 10 Capsules Laxative A07A- Intestinal Anti-infective Anti-diarrheal Gastrobiotic 200 mg Tablets Rifiximin 20 Tablets Antidiarrheal Gastrobiotic 550 mg Tablets Rifiximin 30 Tablets Antidiarrheal Nitazode 100 mg/5 ml Suspension Nitazoxanide Bottle 60 ml Antiprotozoal A10B- Oral Anti -diabetics A10-BD - Oral hypoglycemic associations Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 4/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Glimepiride+ Improve glycemic control for type 2 Glimepiride plus 2/30 Tablets 30 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/500 Tablets 20 Tablets Pioglitazone Hcl diabetes Metformin Hcl + Improve glycemic control for type 2 Bioglitaplus 15/850 Tablets 20 Tablets Pioglitazone Hcl diabetes A10BX - Other anti diabetics Control the elevation of blood sugar Megy One 10 mg Tablets Mitiglinide 20 Tablets after eating B- Blood and blood forming organs B01A - Anti-thrombotic agents Andorivaban 10 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 15 mg F.C Tablets Rivaroxaban 20 Tablets Anticoagulants Andorivaban 20
    [Show full text]
  • Specifications of Approved Drug Compound Library
    Annexure-I : Specifications of Approved drug compound library The compounds should be structurally diverse, medicinally active, and cell permeable Compounds should have rich documentation with structure, Target, Activity and IC50 should be known Compounds which are supplied should have been validated by NMR and HPLC to ensure high purity Each compound should be supplied as 10mM solution in DMSO and at least 100µl of each compound should be supplied. Compounds should be supplied in screw capped vial arranged as 96 well plate format.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Sulfonylurea Stimulation of Insulin Secretion Peter Proks,1 Frank Reimann,2 Nick Green,1 Fiona Gribble,2 and Frances Ashcroft1
    Sulfonylurea Stimulation of Insulin Secretion Peter Proks,1 Frank Reimann,2 Nick Green,1 Fiona Gribble,2 and Frances Ashcroft1 Sulfonylureas are widely used to treat type 2 diabetes smooth, and skeletal muscle, and some brain neurones. In because they stimulate insulin secretion from pancre- all these tissues, opening of KATP channels in response to atic ␤-cells. They primarily act by binding to the SUR metabolic stress leads to inhibition of electrical activity. subunit of the ATP-sensitive potassium (KATP) channel Thus they are involved in the response to both cardiac and and inducing channel closure. However, the channel is cerebral ischemia (2). They are also important in neuronal still able to open to a limited extent when the drug is regulation of glucose homeostasis (3), seizure protection bound, so that high-affinity sulfonylurea inhibition is not complete, even at saturating drug concentrations. (4), and the control of vascular smooth muscle tone (and, thereby, blood pressure) (5). KATP channels are also found in cardiac, skeletal, and smooth muscle, but in these tissues are composed of The KATP channel is a hetero-octameric complex of two different SUR subunits that confer different drug different types of protein subunits: an inwardly rectifying sensitivities. Thus tolbutamide and gliclazide block Kϩ channel, Kir6.x, and a sulfonylurea receptor, SUR (6,7). ␤ ϩ channels containing SUR1 ( -cell type), but not SUR2 Kir6.x belongs to the family of inwardly rectifying K (cardiac, smooth muscle types), whereas glibenclamide, (Kir) channels and assembles as a tetramer to form the glimepiride, repaglinide, and meglitinide block both types of channels.
    [Show full text]
  • Pharmacokinetic and Pharmacodynamic Modeling of Oral
    Liu et al. BMC Pharmacology and Toxicology (2017) 18:54 DOI 10.1186/s40360-017-0161-6 RESEARCH ARTICLE Open Access Pharmacokinetic and pharmacodynamic modeling of oral mitiglinide on glucose lowering in healthy Chinese volunteers Shijia Liu1, Peidong Chen2, Yang Zhao3, Guoliang Dai1, Bingting Sun2, Yao Wang1, Anwei Ding2 and Wenzheng Ju1* Abstract Background: Mitiglinide is a widely used agent for diabetic treatment. We established a pharmacokinetic- pharmacodynamic (PK-PD) model to illustrate the relationship between mitiglinide plasma concentration and its glucose lowering effects in healthy volunteers. Methods: The volunteers participated in the test after the administration of a single dose of 10 mg mitiglinide. The drug concentration in Plasma and the values of glucose levels were determined by LC-MS/MS assay and hexokinase method. A PK-PD model was established with a series of equations to describe the relationship between plasma medicine and glucose, and the equations were solved numerically and fitted to the data with the Phoenix NLME software. Results: The results of the two-compartment model analysis were based on the maximum likelihood criterion and visual inspection of the fittings. The terminal elimination half-life (t1/2) was 1.69 ± 0.16 h and the CL/F was 7.80 ± 1.84 L/h. The plasma glucose levels began to decline by 0.2 h, and hit its bottom decreasing values of 2.6 mg/L at 0.5 h after administration. The calculated parameter and fitting curve indicated that the model established in our experiment fitted well. Conclusions: A PK/PD model illustrates that the relationship between mitiglinide concentration in plasma and glucose lowering effect in healthy volunteers was established.
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • The Claimed Intermediate Online Database | Drug Names to Search: Control F (PC) Command F (Mac) Open & Search in Ibooks App (Ipad)
    The Claimed Intermediate Online Database | Drug Names www.tcipatent.com To search: Control F (PC) Command F (Mac) Open & search in iBooks app (iPad) Drug Name Abiraterone Acetaminophen Adefovir Dipivoxil Agomelatine Albendazole Alendronic acid Alfentanil Aliskiren Allopurinol Almorexant Almotriptan Alogliptin Alosetron Alprostadil Alvimopan www.tcipatent.com Ambrisentan Aminaphtone Amisulpride Amlodipine Amorolfine Amphetamine Amprenavir Amrubicin Amylmetacresol Anagrelide Anastrozole www.tcipatent.com Apixaban Aprepitant Arformoterol Argatroban Aripiprazole Armodafinil Artemether Artemisinin Asenapine Aspirin Atazanavir www.tcipatent.com Atomoxetine Atorvastatin Atorvastatin ( Rosuvastatin Ezetimibe Linezolid ) Atovaquone Azacitidine Azilsartan Azilsartan medoxomil Azithromycin Baclofen Bazedoxifene Bendamustine www.tcipatent.com Benidipine Betaxolol Bexarotene Biapenem Bicalutamide Bimatoprost Bimatoprost ( Latanoprost Travoprost ) Bisoprolol Bivalirudin Boceprevir Bortezomib www.tcipatent.com Bosentan Brinzolamide Bromfenac Buclizine Buprenorphine Bupropion Cabazitaxel Cabazitaxel ( Docetaxel Paclitaxel ) Candesartan cilexetil Capecitabine Carbabenzpyride Caspofungin Cefamandole www.tcipatent.com Cefdinir Cefditoren pivoxil Cefepime Cefixime Cefoperazone Cefotaxime Cefozopran Cefpodoxime Cefpodoxime proxetil Ceftaroline fosamil Ceftobiprole www.tcipatent.com Ceftobiprole medocaril Ceftriaxone Celecoxib Cetirizine Cevimeline Chloroquine Chlorothiazide Cidofovir Cilastatin Cilazapril Cinacalcet www.tcipatent.com Ciprofloxacin Cisatracurium
    [Show full text]
  • Differences Between Mitiglinide/Voglibose Fixed- Dose
    94 Original Article Differences between Mitiglinide/Voglibose Fixed- dose Combination and Glimepiride in Modifying Low- density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study Authors S. Tani1, 2, K. Nagao2, A. Hirayama2 Affiliations 1 Department of Health Planning Center, Nihon University Hospital, Tokyo Japan 2 Division of Cardiology, Department of Medicine, Nihon University School of Medicine, Tokyo Japan Key words Abstract nificantly. In the mitiglinide/voglibose group, ●▶ glimepiride ▼ serum LDL-C levels did not change, while sd-LDL ●▶ LDL-heterogeneity Purpose: The purpose of this study was to levels and sd-LDL/LDL-C decreased significantly ●▶ mitiglinide/voglibose ( − 8.6 % and − 7.9 %) and LDL-C/apoB increased ­fixed-dose­combination compare the effects of mitiglinide/voglibose fixed-dose combination and glimepiride on significantly (5.8 %). Fasting blood glucose levels low-density lipoprotein (LDL)-heterogeneity in tended to be reduced to a greater extent in the type-2 diabetic patients with unstable glycemic glimepiride group than in the mitiglinide/voglib- control after treatment with dipeptidyl pepti- ose group ( − 13.9 % vs. − 8.4 %, p = 0.08), while dase-4 (DPP-4) inhibitors. the rate of reduction of HbA1c levels tended Methods: This was an open-label pilot study in to be higher in the mitiglinide/voglibose group which type-2 diabetic patients were randomly than in the glimepiride group ( − 6.9 % vs. − 3.4 %, assigned to the mitiglinide/voglibose (fixed-dose p = 0.09), suggesting differences in fluctuating combination of mitiglinide 10 mg and voglibose blood glucose levels between the 2 groups. 0.2 mg, n = 14) or glimepiride (0.5 mg, n = 16).
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,888,382 B2 Kiyono Et A]
    US007888382B2 (12) United States Patent (10) Patent N0.: US 7,888,382 B2 Kiyono et a]. (45) Date of Patent: Feb. 15, 2011 (54) COMBINED PHARMACEUTICAL 2005/0197376 A1* 9/2005 Kayakiri et al. ........... .. 514/394 PREPARATION FOR TREATMENT OF TYPE 2 DIABETES FOREIGN PATENT DOCUMENTS EP 1 532 979 5/2005 (75) Inventors: Yuji Kiyono, Tokyo (JP); Yoshio JP 2001-316293 11/2001 Okubo, Tokyo (JP); Katsumi Hontani, WO 2007/033292 3/2007 Tokyo (JP); Imao Mikoshiba, Tokyo (JP); Kazuma Ojima, AZumino (JP) OTHER PUBLICATIONS International Search Report issued Jul. 5, 2006 in the International (73) Assignee: Kissei Pharmaceutical Co., Ltd., (PCT) Application of which the present application is the US. Nagano (JP) National Stage. K. Ojima et al., “Pharmacological and Clinical Pro?le of Mitiglinide ( * ) Notice: Subject to any disclaimer, the term of this Calcium Hydrate (Glufast®), A New Insulinotropic Agent With patent is extended or adjusted under 35 Rapid Onset”, Folia Pharmacol. Jpn. (Nippon Yakurigaku Zasshi), 2004, vol. 124, No. 4, pp. 245-255 (English Abstract enclosed). U.S.C. 154(b) by 102 days. K. Ojima et al., “Rapid Onset-Insulinotropic Effect of Mitiglinide Calcium Dihydrate (KAD-1229), A Novel Antipostprandial (21) Appl. No.: 11/918,654 Hyperglycemic Agent”, Jpn. Pharmacol Ther, 2004, vol. 32, No. 2, pp. 73-80. (22) PCT Filed: Apr. 18,2006 R. F. Coniffet al., “Multicenter, Placebo-Controlled Trial Comparing Acarbose (BAY g 5421) With Placebo, Tolbutamide, and (86) PCT No.: PCT/JP2006/308110 Tolbutamide-Plus-Acarbose in Non-Insulin-Dependent Diabetes Mellitus”, The American Journal of Medicine, vol. 98, pp.
    [Show full text]
  • Development and Validation of an LC-MS/MS Method for The
    Printed in the Republic of Korea ANALYTICAL SCIENCE & TECHNOLOGY Vol. 32 No. 2, 35-47, 2019 https://doi.org/10.5806/AST.2019.32.2.35 Development and validation of an LC-MS/MS method for the simultaneous analysis of 26 anti-diabetic drugs in adulterated dietary supplements and its application to a forensic sample Nam Sook Kim†, Geum Joo Yoo†, Kyu Yeon Kim, Ji Hyun Lee, Sung-Kwan Park, Sun Young Baek, and Hoil Kang★ Division of Advanced Analysis, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Osong Health Technology Administration Complex, 187 Osongsaengmyeong2-ro, Osongeup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do 363-700, Korea (Received September 18, 2018; Revised February 21, 2019; Accepted March 7, 2019) Abstract In this study, high-performance liquid chromatography–tandem mass spectrometry (HPLC-MS/ MS) was employed to detect 26 antidiabetic compounds in adulterated dietary supplements using a simple, selective method. The work presented herein may help prevent incidents related to food adulteration and restrict the illegal food market. The best separation was obtained on a Shiseido Capcell Pak® C18 MG- II (2.0 mm × 100 mm, 3 µm), which improved the peak shape and MS detection sensitivity of the target compounds. A gradient elution system composed of 0.1 % (v/v) formic acid in distilled water and methanol at a flow rate of 0.3 mL/min for 18 min was utilized. A triple quadrupole mass spectrometer with an electrospray ionization source operated in the positive or negative mode was employed as the detector. The developed method was validated as follows: specificity was confirmed in the multiple reaction monitoring mode using the precursor and product ion pairs.
    [Show full text]